VXA-CoV2-3.3

Phase 2Biologic

VVaxart

VXA-CoV2-3.3 is one of 21 biologic programs targeting COVID-19. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

COVID-19Active, not recruiting

SARS-Cov2Active, not recruiting

COVID-19Phase 2

Active, not recruiting

SARS-Cov2Phase 2

Active, not recruiting

Competition

Competitive Landscape

1931 competitors in COVID-19

#DrugCompanyPhaseTrials

Singulair

AstraZeneca

Preclinical

1 2

VXA-CoV2-3.3

VVaxart

Phase 2

1 3

Proventil

Mylan Pharmaceuticals Inc

Preclinical

1 4

Aquasol E

NNational Eye Institute (NEI)

Preclinical

1 5

Nitrostat

VViatris Specialty LLC

Preclinical

1 6

Benadryl

PParkedale

Preclinical

1 7

Rayaldee

OOrganon and Co

Preclinical

1 8

SARS-COV-2 VACCINE

Moderna

Preclinical

2 9

Achromycin V

WWyeth-Lederle Vaccines

Statins

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 2Active, not recruiting

SARS-Cov2

NCT06672055

Clinical

Trials by Indication[1]

SARS-CoV21 trial

A Phase 2b, Double-Blind, Multi-Center, Randomized, Comparator-Controlled Trial to Determine the Relative Efficacy, Safety, and Immunogenicity of the Investigational Oral SARS-CoV-2 Vaccine Tablet Against Currently Approved/Authorized mRNA COVID-19 Injectable Booster Vaccine in Adults Previously Immunized Against COVID-19 Infection

Active, not recruiting·VVaxart·Phase 2·NCT06672055·5,485 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for VXA-CoV2-3.3. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — VXA-CoV2-3.3 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for VXA-CoV2-3.3. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Vaxart company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 2[1]
Company: VVaxart

VXA-CoV2-3.3

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Trials by Indication[1]

SARS-CoV21 trial

References

Drug Info

Quick Facts

Related News